Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 291-310

  Atkins, William M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allosterism; CYP; Drug metabolism; Enzyme kinetics

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4;

CATALYSIS; CONFORMATIONAL TRANSITION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME SUBSTRATE COMPLEX; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REACTION ANALYSIS; REVIEW; SYSTEMATIC REVIEW; X RAY CRYSTALLOGRAPHY; XENOBIOTIC METABOLISM;

ANIMALS; BINDING SITES; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MODELS, BIOLOGICAL;

EID: 13844308070     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.100004     Document Type: Review

References (100)

1. Guengerich FP. 2002. Cytochrome P450 enzymes in the generation of commercial products. Nat. Rev. Drug Discov. 1:359-66
2. Coon MJ, Ding XX, Pernecky SJ, Vaz AD. 1992. Cytochrome P450: progress and predictions. FASEB J. 6:669-73
3. Wienkers LC. 2001. Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. J. Pharmacol. Toxicol. Methods 45(1):79-84
4. Szklarz GD, Halpert JR. 1998. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab. Dispos. 26(12):1179-84
5. MacCoss M, Baillie TA. 2004. Organic chemistry in drug discovery. Science 303(5665):1810-13
6. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. 2001. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 41(11):1149-79
7. Shou M. 2002. Kinetic analysis for multiple substrate interaction at the active site of cytochrome P450. Methods Enzymol. 357:261-76
8. Shou M, Lin Y, Lu P, Tang C, Mei Q, et al. 2001 Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab. 2:17-36
9. Houston JB, Kenworthy KE. 2000. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 28:246-54
10. Hlavica P, Lewis DF. 2001. Allosteric phenomena in cytochrome P450-catalyzed monooxygenations. Eur. J. Biochem. 268: 4817-32
11. Tracy TS. 2003 Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr. Drug Metab. 4:341-46
12. Lasker JM, Huang M-T, Conney AH. 1982. In vivo activation of zoxazolamine metabolism by flavone. Science 216:1419-21
13. Huang MT, Chang RL, Fortner JG, Conney AH. 1981. Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. J. Biol. Chem. 256:6829-36
14. Schwab GE, Raucy JL, Johnson EF. 1988. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol. Pharmacol. 33:493-99
15. Shou M, Grogan J, Mencewicz JA, Krausz KW, Gonzalez FJ, et al. 1994. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-55
16. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, et al. 1998. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-47
17. 1H NMR study. J. Am. Chem. Soc. 116(11):4866-73
18. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, et al. 1999. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J. Pharmacol Exp. Ther. 291:1068-74
19. Egnell AC, Houston B, Boyer S. 2003. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J. Pharmacol. Exp. Ther. 305:1251-62
20. Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang SM, Tracy TS. 2001. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur. J. Pharm. Sci. 14:47-57
21. Ekins S, Ring BJ, Binkley SN, Hall SD, Wrighton SA. 1998. Autoactivation and activation of the cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 36:642-51
22. Tracy TS, Hutzler JN, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. 2002. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab. Dispos. 30:385-90
23. He YA, Roussel F, Halpert JR. 2003. Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch. Biochem. Biophys. 409:92-101
24. Hutzler JM, Hauer MJ, Tracy TA. 2001. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. 29:1029-34
25. Khan KK, He YA, Domanski TL, Halpert JR. 2002. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol. Pharmacol. 61:495-506
26. Ngui JS, Chen Q, Shou M, Wang RW, Stearns RA, et al. 2001. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab. Dispos. 29:877-86
27. Edelstein SJ, Changera JP. 1998. Allosteric transitions of the acetylcholine receptor. See Ref. 99, pp. 121-84
28. Ackers GK. 1998. Deciphering the molecular code of hemoglobin allostery. See Ref. 99, pp. 185-253
29. Wyman J, Gill SJ. 1990. Allosteric systems. In Binding and Linkage: Functional Chemistry of Biological Macromolecules, pp. 123-63. Mill Valley, CA: Univ. Sci. Books
30. Szczesna-Skorupa E, Mallah B, Kemper B. 2003. Fluorescence resonance energy transfer analysis of cytochromes P450 2C2 and 2E1 molecular interactions in living cells. J. Biol. Chem. 278:31269-76
31. Myasoedova KN, Tsuprun VL. 1993. Cytochrome P-450: hexameric structure of the purified LM4 form. FEBS Lett. 325:251-54
32. Atkins WM, Lu WD, Cook DL. 2002. Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from "distributive catalysis." J. Biol. Chem. 277(36):33258-66
33. Galetin A, Clarke SE, Houston JB. 2002. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 30:1512-22
34. Tang W, Stearns RA. 2001. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug Metab. 2(2):185-98
35. Wang RW, Newton DJ, Scheri TD, Lu AY. 1997. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab. Dispos. 25(4):502-7
36. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. 2000. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28:360-66
37. Galetin A, Clarke SE, Houston JB. 2003. Multisite kinetic analysis of interactions between prototypical CYP3A4 substrates: midazolam, testosterone, and nifedipine. Drug. Metab. Dispos. 31(9):1108-16
38. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. 1997. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-81
39. Patki KC, Von Moltke LL, Greenblatt DJ. 2003. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos. 31(7):938-44
40. Atkins WM, Wang RW, Lu AY. 2001. Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. Chem. Res. Toxicol. 14:338-47
41. Koley AP, Buters JTM, Robinson RC, Markowitz A, Friedman FK. 1997. Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone J. Biol. Chem. 272: 3149-52
42. Koley AP, Robinson RC, Markowitz A, Friedman FK. 1997. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem. Pharmacol. 53:455-60
43. Koley AP, Buters JT, Robinson RC, Markowitz A, Friedman FK. 1995. CO binding kinetics of human cytochrome P450 3A4. Specific interaction of substrates with kinetically distinguishable conformers. J. Biol Chem. 270(10):5014-18
44. Davydov DR, Halpert JR, Renaud JP, Hui Bon Hoa G. 2003. Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem. Biophys. Res. Commun. 312:121-30
45. Schrag ML, Wienkers LC. 2000. Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). Drug Metab. Dispos. 28(10):1198-201
46. Hutzler JM, Powers FJ, Wynalda MA, Wienkers LC. 2003. Effect of carbonate anion on cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple oxygenating species. Arch. Biochem. Biophys. 417(2):165-75
47. Maenpaa JVA, Hall SD, Ring BJ, Strom SC, Wrighton SA. 1998. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-55
48. Guengerich FP. 1999. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39:1-17
49. Schenkman JB, Jansson I. 2003. The many roles of cytochrome b5. Pharmacol. Ther. 97(2):139-52
50. Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich FP. 1996. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH cytochrome P450 reductase system and studies with apo-cytochrome b5. J. Biol. Chem. 271(44):27438-44
51. Gilep AA, Guryev OL, Usanov SA, Estabrook RW. 2001 Apo-cytochrome b5 as an indicator of changes in heme accessability: preliminary studies with cytochrome P450 3A4. J. Inorg. Biochem. 87(4):237-44
52. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, et al. 2002. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr. Purif. 24(3):329-37
53. Guryev OL, Gilep AA, Usanov SA, Estabrook RW. 2001. Interaction of apocytochrome b5 with cytochromes P450-3A4 and P45017A: relevance of heme transfer reactions. Biochemistry 40(16): 5018-31
54. Modi S, Gilham DE, Sutcliffe MJ, Lian LY, Primrose WU, et al. 1997. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 36(15): 4461-70
55. Hanna IH, Krauser JA, Cai H, Kim MS, Guengerich FP. 2001. Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. J. Biol. Chem. 276(43):39553-61
56. Loughran PA, Roman LJ, Miller RT, Masters BS. 2001. The kinetic and spectral characterization of the E. coli-expressed mammalian CYP4A7: cytochrome b5 effects vary with substrate. Arch. Biochem. Biophys. 385(2):311-22
57. Cupp-Vickery J, Andersen R, Hatziris Z. 2000. Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc. Natl. Acad. Sci. USA 97(7):3050-55
58. Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, et al. 2003. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 42(51):15068-77
59. Dabrowski MJ, Schrag ML, Wienkers LC, Atkins WM. 2000. Pyrene-pyrene complexes at the active site of cytochrome P4503A4: evidence for a multiple substrate binding site. J. Am. Chem. Soc. 124(40):11866-67
60. Segel IH. 1993. Multisite and allosteric enzymes. In Enzyme Kinetics, pp. 346-404. New York: Wiley
61. Shen L, Fitzloff JF, Cook CS. 2004. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab. Dispos. 32:186-96
62. Beechem JM, Gratton E, Ameloot M, Knutson JR, Brand L. 1991. The global analysis of fluorescence and intensity and anisotropy decay data: second generation theory and program. In Topics in Fluorescence Spectroscopy, ed. JR Lakowicz, vol. 2, pp. 241-98. New York: Plenum Press
63. Lin Y, Lu P, Tang C, Mei Q, Sandig G, et al. 2001. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab. Dispos. 29:368-74
64. Kenworthy KE, Clarke SE, Andrews J, Houston JB. 2001. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 29:1644-51
65. Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, Rushmore TH. 2001. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 276(3):2256-62
66. Hosea NA, Miller GP, Guengerich FP. 2000. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-39
67. Domanski TL, He YA, Khan KK, Roussel F, Wang Q, Halpert JR. 2001. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40(34):10150-60
68. Khan KK, He YQ, Domanski TL, Halpert JR. 2002. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol. Pharmacol 61(3):495-506
69. Davydov DR, Kumar S, Halpert JR. 2002. Allosteric mechanisms in P450eryF probed with 1-pyrenebutanol, a novel fluorescent substrate. Biochem. Biophys. Res. Commun. 294(4):806-12
70. Yoon MY, Campbell AP, Atkins WM. 2004. "Allosterism" in the elementary steps of the cytochrome P450 reaction cycle. Drug Metab. Rev. 36:1-12
71. Harlow GR, Halpert JR. 1998. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hy droxylation kinetics. Proc. Natl. Acad. Sci. USA 95(12):6636-41
72. Domanski TL, He YA, Harlow GR, Halpert JR. 2000. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J. Pharmacol. Exp. Ther. 293(2):585-91
73. Iyer KR, Jones JP, Darbyshire JF, Trager WF. 1997. Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4′- dimethylbiphenyl by cytochrome P450: relationship between distance of methyl groups and masking of the intrinsic isotope effect. Biochemistry 36(23):7136-43
74. Korzekwa KR, Trager WF, Gillette JR. 1989. Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: cytochrome P-450. Biochemistry. 28(23):9012-18
75. Nelson SD, Trager WF. 2003. The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab. Dispos. 31(12):1481-98
76. Rock DA, Perkins BN, Wahlstrom J, Jones JP. 2003. A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy omega product formation. Arch. Biochem. Biophys. 416(1):9-16
77. Reed JR, Hollenberg PF. 2003. Comparison of substrate metabolism by cytochromes P450 2B1, 2B4, and 2B6: relationship of heme spin state, catalysis, and the effects of cytochrome b5. J. Inorg. Biochem. 93(3-4):152-60
78. Gorsky LD, Koop DR, Coon MJ. 1984. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction. J. Biol. Chem. 259(11):6812-17
79. Atkins WM, Sugar SG. 1987. Metabolic switching in cytochrome p450cam: deuterium isotope effects on regiospecificity and the monooxygenase/oxidase ratio. J. Am. Chem. Soc. 109:3754-60
80. Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, Tracy TS. 2003. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch. Biochem. Biophys. 410(1):16-24
81. Wester MR, Stout CD, Johnson EF. 2002. Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5. Methods Enzymol. 357:73-79
82. Scott EE, Spatzenegger M, Halpert JR. 2001. A truncation of 2B subfamily cytochrome P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch. Biochem. Biophys. 395(1): 57-68
83. Cosme J, Johnson EF. 2000. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J. Biol. Chem. 275(4):2545-53
84. Hsu PY, Wang LH. 2003. Protein engineering of thromboxane synthase: conversion of membrane-bound to soluble form. Arch. Biochem. Biophys. 416(1):38-46
85. Sueyoshi T, Park LJ, Moore R, Juvonen RO, Negishi M. 1995. Molecular engineering of microsomal P450 2a-4 to a stable, water-soluble enzyme. Arch. Biochem. Biophys. 322(1):265-71
86. Tennant M, McRee DE. 2001. The first structure of a microsomal P450-implications for drug discovery. Curr. Opin. Drug Discov. Dev. 4(5):671-77
87. Lepesheva GI, Waterman MR. 2004. CYP51 - the omnipotent P450. Mol. Cell Endocrinol. 215(1-2):165-70
88. Li H, Poulos TL. 1996. Conformational dynamics in cytochrome P450-substrate interactions. Biochimie 78(8-9):695-99
89. Poulos TL. 1988. Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design. Pharm. Res. 5(2):67-75
90. Schlichting I, Berendzen J, Chu K, Stock AM, Maves SA, et al. 2000. The catalytic pathway of cytochrome p450cam at atomic resolution. Science 287(5458):1615-22
91. Ravichandran KG, Boddupalli SS, Hasermann CA, Peterson JA, Deisenhofer J. 1993. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science 261(5122): 731-36
92. Wester MR, Johnson EF, Marques-Soares C, Dijols S, Dansette PM, et al. 2003. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution: evidence for an induced fit model of substrate binding. Biochemistry 42(31):9335-45
93. Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D, Stout CD. 2003. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: evidence for multiple substrate binding modes. Biochemistry 42(21):6370-79
94. Strickler M, Goldstein BM, Maxfield K, Shireman L, Kim G, et al. 2003. Crystallographic studies on the complex behavior of nicotine binding to P450cam (CYP101). Biochemistry 42(41):11943-50
95. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. 2003. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424(6947):464-68
96. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF. 1989. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17(3):265-70
97. Scott EE, He YA, Wester MR, White MA, Chin CC, et al. 2003. An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. Proc. Natl. Acad. Sci. USA 100(23):13196-201
98. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. 2004. Structure of human microsomal cytochrome P450 2C8: evidence for a peripheral fatty acid binding site. J. Biol. Chem. 279:9497-503
99. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, et al. 2004. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305(5684):683-86
100. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. 2004. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05′ resolution. J. Biol. Chem. In press